Amivantamab is an EGFR-MET bispecific antibody used intravenously—often with lazertinib—for EGFR-mutated advanced non–small-cell lung cancer (NSCLC). The phase 2 SKIPPirr trial tested four prophylactic strategies on top of standard premedication (antihistamines, antipyretics, intravenous dexamethasone 10 mg) in patients with advanced EGFR exon 19 deletion or L858R–mutated NSCLC previously treated with osimertinib and platinum chemotherapy.
